Table 5.

Monotherapy clinical trials on Ramipril in T2DM patients

Researchers	Study population	Methodology	Results/Comment
Trevisan and Tiengo[37]	T2DM; n=122	Ramipril 1.25 mg/day; duration: 6 months	Low-dose ACE inhibition with ramipril could arrest the progressive rise in albuminuria in T2DM patients with persistent microalbuminuria.
Nielsen et al.[38]	T2DM, n= 16	Ramipril (5mg)/day; duration: 6 month	Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric T2DM patients
MICROHOPE Substudy[39]	T2DM; n=3577	Ramipril 10 mg/day vs. placebo and Vitamin E; duration: 4.5 years	Lowered the risk of the combined primary outcome by 25%, myocardial infarction by 22%, stroke by 33%, CV death by 37%, total mortality by 24%, revascularization by 17%, and overt nephropathy by 24%.
			Ramipril was beneficial for CV events and overt nephropathy in T2DM patients

T2DM= Type 2 Diabetes Mellitus